Poly(ADPribose)polymerase inhibitors - the current clinical status

被引：1
|
作者：
Plummer, R. [1 ]
机构：
[1] No Inst Canc Res, Paul Ogorman Bldg, Newcastle Upon Tyne, Tyne & Wear, England
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70464-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
459
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] New inhibitors of poly(ADPribose) polymerase and their potential therapeutic targets
    Cosi, C
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (07) : 1047 - 1071
  • [2] Current status of poly(ADP-ribose) polymerase inhibitors and future directions
    Ohmoto, Akihiro
    Yachida, Shinichi
    ONCOTARGETS AND THERAPY, 2017, 10 : 5195 - 5208
  • [3] STATUS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS IN CLINICAL DEVELOPMENT
    Kummar, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 21 - 21
  • [4] Poly ADP-ribose polymerase inhibitors: science and current clinical development
    Liu, Joyce F.
    Silver, Daniel P.
    CURRENT OPINION IN ONCOLOGY, 2010, 22 (06) : 567 - 572
  • [5] Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology
    Ratnam, Kapila
    Low, Jennifer A.
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1383 - 1388
  • [6] SPECIFIC INHIBITION OF POLY ADPRIBOSE POLYMERASE BY THYMIDINE AND NICOTINAMIDE IN HELA CELLS
    PREISS, J
    SCHLAEGER, R
    HILZ, H
    FEBS LETTERS, 1971, 19 (03) : 244 - +
  • [7] The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions
    Chionh, Fiona
    Mitchell, Gillian
    Lindeman, Geoffrey J.
    Friedlander, Michael
    Scott, Clare L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (03) : 197 - 211
  • [8] The clinical development of inhibitors of poly(ADP-ribose) polymerase
    Calvert, H.
    Azzariti, A.
    ANNALS OF ONCOLOGY, 2011, 22 : i53 - i59
  • [9] HIF Inhibitors: Status of Current Clinical Development
    Jaleh Fallah
    Brian I. Rini
    Current Oncology Reports, 2019, 21
  • [10] Current status of clinical trials of farnesyltransferase inhibitors
    Karp, JE
    Kaufmann, SH
    Adjei, AA
    Lancet, JE
    Wright, JJ
    End, DW
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) : 470 - 476
12345